1 min read
Three Drugmakers’ Shares Gain After White House Withdraws FDA Nominee
The nomination was for Dr. Heidi Overton to lead the Food and Drug Administration. The three companies have separate FDA matters at different stages.

The White House withdrew Dr. Heidi Overton’s nomination to lead the Food and Drug Administration (FDA) on Wednesday, Nov. 18.
Shares of Capricor Therapeutics (CAPR), Regenxbio (RGNX) and Replimune (REPL) were among Wednesday’s notable gainers following the withdrawal.
The companies have separate FDA matters at different stages. Replimune’s RP1 has received accelerated approval, Capricor’s Deramiocel application is under review, and Regenxbio plans to resubmit RGX-121.